Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intellia Therapeutics, Inc. (NTLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases"
08/03/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback - On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - Plans to present additional clinical data in 2023 from the ongoing NTLA-2001 first-in-human study by year-end - Expects to submit a Clinical Trial Application by year-end for NTLA-3001, Intellia’s first in vivo inser..."
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIA THERAPEUTICS, INC. Intellia Therapeutics, Inc. , a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware , DOES HEREBY CERTIFY: 1. That the name of this corporation is Intellia Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on May 7, 2014 under the name AZRN, Inc. 2. That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Second Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate ..."
06/12/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Intellia Therapeutics Announces New Positive Clinical Data from Phase 1study of"
06/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. from Its Board of Directors CAMBRIDGE, Mass., June 5, 2023 — Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023. “Working with the team at Intellia and seeing the company's transformation from an idea to a leader in genome editing has been one of the most exciting journeys in my career,” said Jean-François Formela, M.D. “I am confident this is just the beginning for John and his team. I can't wait to see Intellia's next chapter and how they will transform the future..."
05/04/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress - Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023 - Plans to submit IND application in mid-2023 for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing next wave of clinical candidates, including NTLA-3001 and NTLA-2003, and advancing novel gene editing capabilities - Ended the first quarter o..."
04/17/2023 8-K Quarterly results
03/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Announces FDA Clearance of Investigational New Drug"
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress - Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema - Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study - Plans to submit IND application in mid-2023 for global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; global pivotal study initiation anticipated by year-end 2023 - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing IND-enabling activities for two alpha-1 antitrypsin deficiency candidates, NTLA-2003 and NTLA-3001; ..."
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones - Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platform - Submit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023 - Submit IND application for NTLA-2002 for the treatment of hereditary angioedema and initiate global Phase 2 study in 1H 2023 - Present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progress first CRISPR-based gene insertion investigational therapy in humans; submit IND or equivalent fi..."
12/01/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/07/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin Amyloidosis at the American Heart Association Scientific Sessions 2022 - Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy - Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both doses tested, with follow-up now reaching four to six months - NTLA-2001 was generally well-tolerated CAMBRIDGE, Mass., Nov. 5, 2022 – Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapeu..."
11/03/2022 8-K Quarterly results
09/16/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin Amyloidosis",
"Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema"
08/04/2022 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Completed dose-escalation portion of the ongoing Phase 1study of NTLA-2001 in patients with transthyretin amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction data in 2H 2022 - Presented updated interim data from the dose-escalation portion of the polyneuropathy arm, establishing deep reductions of disease-causing protein were sustained through 12 months following a single dose of NTLA-2001 - Plans to present interim data for second in vivo CRISPR clinical candidate, NTLA-2002 for hereditary angioedema , in 2H 2022 - Moves to exclusively develop cell therapies leveraging its proprietary allogeneic platform; pivoting to an allogeneic version of..."
06/24/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
03/04/2022 8-K Quarterly results
03/04/2022 8-K Quarterly results
02/28/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein"
02/24/2022 8-K Quarterly results
02/03/2022 8-K Quarterly results
01/06/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022 - Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin amyloidosis; on track to present additional data from Phase 1study in Q1 2022 - Achieve preliminary proof-of-concept for NTLA-2002 in patients with hereditary angioedema based on ongoing first-in-human study; anticipate presenting interim data in 2H 2022 - Establish initial safety and activity profile of NTLA-5001 for acute myeloid leukemia in Phase 1/2a study - Progress in vivo and ex vivo research programs and integrate novel platform technologies; expect to nominate multiple new development candidates in 2022 - Ended 2021 in strong financial position with $1.1 billion in cash"
11/04/2021 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress - Initiated dosing of Cohort 4 in the ongoing Phase 1study of NTLA-2001; data update from completed dose-escalation and initiation of dose-expansion expected in Q1 2022 - Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy - On track to initiate first-in-human studies of NTLA-2002 for hereditary angioedema and NTLA-5001 for acute myeloid leukemia by year-end - Announces nomination of NTLA-3001, its first gene insertion development candidate, for alpha-1 antitrypsin deficiency ; concurrently, Regeneron and Intellia have selected a Factor 9 gene insertion development candidate to advance for hemophilia B - Presented new data on its proprietary and ..."
08/05/2021 8-K Quarterly results
07/02/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among the Company and Goldman Sachs & Co LLC, Jefferies LLC, SVB Leerink LLC, and Barclays Capital Inc., as representatives of the several underwriters listed on Schedule A thereto",
"Opinion of Goodwin Procter LLP regarding the issue of common stock being registered"
06/28/2021 8-K Quarterly results
06/24/2021 8-K Quarterly results
06/22/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy